Should we target HDL cholesterol level in lowering cardiovascular risk?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 10, 2009, Pages 667-672

  Toth, Peter P ^a,b  

^a Preventive Cardiology   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Atherosclerosis; Cholesterol; High density lipoprotein; Meta analysis; Reverse cholesterol transport

Indexed keywords

BEZAFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW;

EID: 72249084345     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.801     Document Type: Review

References (56)

1. Libby P. Atherosclerosis: the new view. Sci Am. 2002; 286: 46-55.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
3. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009; 360: 1851-1861.
4. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504. (Pubitemid 38477774)
5. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295: 1556-1565.
6. Toth PP. High-density lipoprotein: epidemiology, metabolism, and anti-atherogenic effects. Dis Mon. 2001; 47: 369-416.
7. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol. 1988; (4 Suppl A): 5A-10A.
8. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983; 52: 9B-12B.
9. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124 Suppl: S11-20.
10. Genest J, Jr., McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992; 19: 792-802.
11. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001; 358: 2026-2033. (Pubitemid 34084825)
12. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001; 285: 2729-2735.
13. Pearson TA, Bulkley BH, Achuff SC, et al. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol. 1979; 109: 285-295.
14. Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 1979; 109: 296-308. (Pubitemid 10209605)
15. Wolfram RM, Brewer HB, Xue Z, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol. 2006; 98: 711-717. (Pubitemid 44300998)
16. Barter P, Gotto A, LaRosa J, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357: 1301.
17. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002; 90: 139-143.
18. Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004; 20: 1253-1268. (Pubitemid 39120790)
19. Cannon CP. The IDEAL cholesterol: lower is better. JAMA. 2005; 294: 2492-2494.
20. Toth PP, Davidson MH. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008; 57 (5 Suppl High-Dose): S29-36.
21. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
22. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009; 338: b92.
23. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007; 297: 499-508. (Pubitemid 46220805)
24. Brown B, Zhao X, Cheung M. Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. J Clin Lipidol. 2007; 1: 88-94. (Pubitemid 46710835)
25. Ballantyne CM, Reichten JS, Nicholls SJ, et al.; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008; 117: 2458-2466.
26. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345: 1583-1592. (Pubitemid 33126837)
27. Brunzell JD, Hokanson JE. Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. Am J Med. 1999; 107: 16S-18S.
28. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341: 410-418.
29. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001; 285: 1585-1591. (Pubitemid 32240250)
30. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317: 1237-1245. (Pubitemid 17147964)
31. Manninen V, Koskinen R Manttari M, et al. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type Ha subjects in the Helsinki Heart Study. Am J Cardiol. 1990; 66: 24A-27A. (Pubitemid 20280917)
32. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000; 102: 21-27.
33. Goldenberg I, Goldbourt U, Boyko V, et al. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol. 2006; 97: 466-471. (Pubitemid 43190032)
34. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572-2581.
35. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299: 1561-1573.
36. Toth P. Torcetrapib and atherosclerosis: what happened and where do we go from here? Future Lipidol. 2007; 2: 277-284.
37. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP inhibition and HDL Elevation). Circulation. 2008; 118: 2506-2514.
38. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007; 117: 746-756. (Pubitemid 46348533)
39. Brewer HB, Jr., Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004; 24: 1755-1760.
40. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000; 101: 2510-2517. (Pubitemid 30366256)
41. Garner B, Witting PK, Waldeck AR, et al. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem. 1998; 273: 6080-6087.
42. Xia P, Vadas MA, Rye KA, et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem. 1999; 274: 33143-33147. (Pubitemid 129535357)
43. Li XP, Zhao SP, Zhang XY, et al. Protective effect of high density lipo-protein on endothelium-dependent vasodilatation. Int J Cardiol. 2000; 73: 231-236.
44. Noter JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004; 113: 569-581. (Pubitemid 38542506)
45. Tso C, Martinic G, Fan WH, et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 2006; 26: 1144-1149. (Pubitemid 43732125)
46. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001; 276: 34480-34485. (Pubitemid 37384437)
47. Nofer JR, Walter M, Kehrel B, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol. 1998; 18: 861-869.
48. Yu S, Yarnell JW, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis. 2003; 166: 331-338. (Pubitemid 36071691)
49. Toth PP, Davidson MH. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol. 2004; 19: 374-379.
50. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290: 2292-2300. (Pubitemid 37430562)
51. Ansell BJ, Fonarow GC, Fogelman AM. High-density Lipoprotein: Is it always atheroprotective? Curr Atheroscler Rep. 2006; 8: 405-411.
52. Heinecke JW. The HDL proteome: a marker - and perhaps mediator - of coronary artery disease. J Lipid Res. 2009; 50 Suppl: S167-171.
53. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003; 108: 2751-2756. (Pubitemid 37498976)
54. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008; 118: 1259-1267.
55. Toth PP. Novel therapies for increasing serum levels of HDL. Endocrinol Metab Clin North Am. 2009; 38: 151-170.
56. Toth PP. When high is low: raising low levels of high-density lipoprotein cholesterol. Curr Cardiol Rep. 2008; 10: 488-496.